What is the current valuation of the Rare Disease Genome Editing Market?

The market valuation was 4.64 USD Billion in 2024. Read More

What is the projected market size for the Rare Disease Genome Editing Market by 2035?

The market is projected to reach 10.5 USD Billion by 2035. Read More

What is the expected CAGR for the Rare Disease Genome Editing Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 7.71%. Read More

Which technologies are leading the Rare Disease Genome Editing Market?

Key technologies include CRISPR-Cas9, TALEN, Zinc Finger Nucleases, and Meganucleases. Read More

What was the market size for CRISPR-Cas9 technology in 2024?

The market size for CRISPR-Cas9 technology was 2.32 USD Billion in 2024. Read More

How much is the Gene Therapy application segment expected to grow by 2035?

The Gene Therapy application segment is projected to grow from 1.5 USD Billion in 2024 to 3.5 USD Billion by 2035. Read More

Which companies are considered key players in the Rare Disease Genome Editing Market?

Key players include Vertex Pharmaceuticals, Sangamo Therapeutics, and CRISPR Therapeutics, among others. Read More

What is the expected market size for Sickle Cell Disease treatment by 2035?

The market size for Sickle Cell Disease treatment is projected to reach 2.5 USD Billion by 2035. Read More

What was the market valuation for Drug Development applications in 2024?

The market valuation for Drug Development applications was 1.0 USD Billion in 2024. Read More

How do academic institutions contribute to the Rare Disease Genome Editing Market?

Academic institutions are expected to grow from 0.58 USD Billion in 2024 to 1.25 USD Billion by 2035. Read More

Rare Disease Genome Editing Market

ID: MRFR/HC/41851-HCR

128 Pages

Rahul Gotadki

Last Updated: April 15, 2026

Rare Disease Genome Editing Market Research Report: Size, Share, Trend Analysis By Technology (CRISPR-Cas9, TALEN, Zinc Finger Nucleases, Meganucleases), By Applications (Gene Therapy, Cell Therapy, Genomic Research, Drug Development), By End Use (Pharmaceutical Companies, Research Institutions, Academic Institutions, Contract Research Organizations), By Target Rare Diseases (Cystic Fibrosis, Sickle Cell Disease, Hemophilia, Duchenne Muscular Dystrophy) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Rare Disease Genome Editing Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Technology (USD Billion) | |
  1. 4.1.1 CRISPR-Cas9 | |
  2. 4.1.2 TALEN | |
  3. 4.1.3 Zinc Finger Nucleases | |
  4. 4.1.4 Meganucleases |
2. 4.2 Healthcare, BY Application (USD Billion) | |
  1. 4.2.1 Gene Therapy | |
  2. 4.2.2 Cell Therapy | |
  3. 4.2.3 Genomic Research | |
  4. 4.2.4 Drug Development |
3. 4.3 Healthcare, BY End-Use (USD Billion) | |
  1. 4.3.1 Pharmaceutical Companies | |
  2. 4.3.2 Research Institutions | |
  3. 4.3.3 Academic Institutions | |
  4. 4.3.4 Contract Research Organizations |
4. 4.4 Healthcare, BY Target Rare Diseases (USD Billion) | |
  1. 4.4.1 Cystic Fibrosis | |
  2. 4.4.2 Sickle Cell Disease | |
  3. 4.4.3 Hemophilia | |
  4. 4.4.4 Duchenne Muscular Dystrophy |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Vertex Pharmaceuticals (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Sangamo Therapeutics (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 CRISPR Therapeutics (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Editas Medicine (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Intellia Therapeutics (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Bluebird Bio (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Regeneron Pharmaceuticals (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Amgen (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Novartis (CH) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TECHNOLOGY |
7. 6.4 US MARKET ANALYSIS BY APPLICATION |
8. 6.5 US MARKET ANALYSIS BY END-USE |
9. 6.6 US MARKET ANALYSIS BY TARGET RARE DISEASES |
10. 6.7 CANADA MARKET ANALYSIS BY TECHNOLOGY |
11. 6.8 CANADA MARKET ANALYSIS BY APPLICATION |
12. 6.9 CANADA MARKET ANALYSIS BY END-USE |
13. 6.10 CANADA MARKET ANALYSIS BY TARGET RARE DISEASES |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TECHNOLOGY |
16. 6.13 GERMANY MARKET ANALYSIS BY APPLICATION |
17. 6.14 GERMANY MARKET ANALYSIS BY END-USE |
18. 6.15 GERMANY MARKET ANALYSIS BY TARGET RARE DISEASES |
19. 6.16 UK MARKET ANALYSIS BY TECHNOLOGY |
20. 6.17 UK MARKET ANALYSIS BY APPLICATION |
21. 6.18 UK MARKET ANALYSIS BY END-USE |
22. 6.19 UK MARKET ANALYSIS BY TARGET RARE DISEASES |
23. 6.20 FRANCE MARKET ANALYSIS BY TECHNOLOGY |
24. 6.21 FRANCE MARKET ANALYSIS BY APPLICATION |
25. 6.22 FRANCE MARKET ANALYSIS BY END-USE |
26. 6.23 FRANCE MARKET ANALYSIS BY TARGET RARE DISEASES |
27. 6.24 RUSSIA MARKET ANALYSIS BY TECHNOLOGY |
28. 6.25 RUSSIA MARKET ANALYSIS BY APPLICATION |
29. 6.26 RUSSIA MARKET ANALYSIS BY END-USE |
30. 6.27 RUSSIA MARKET ANALYSIS BY TARGET RARE DISEASES |
31. 6.28 ITALY MARKET ANALYSIS BY TECHNOLOGY |
32. 6.29 ITALY MARKET ANALYSIS BY APPLICATION |
33. 6.30 ITALY MARKET ANALYSIS BY END-USE |
34. 6.31 ITALY MARKET ANALYSIS BY TARGET RARE DISEASES |
35. 6.32 SPAIN MARKET ANALYSIS BY TECHNOLOGY |
36. 6.33 SPAIN MARKET ANALYSIS BY APPLICATION |
37. 6.34 SPAIN MARKET ANALYSIS BY END-USE |
38. 6.35 SPAIN MARKET ANALYSIS BY TARGET RARE DISEASES |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END-USE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY TARGET RARE DISEASES |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TECHNOLOGY |
45. 6.42 CHINA MARKET ANALYSIS BY APPLICATION |
46. 6.43 CHINA MARKET ANALYSIS BY END-USE |
47. 6.44 CHINA MARKET ANALYSIS BY TARGET RARE DISEASES |
48. 6.45 INDIA MARKET ANALYSIS BY TECHNOLOGY |
49. 6.46 INDIA MARKET ANALYSIS BY APPLICATION |
50. 6.47 INDIA MARKET ANALYSIS BY END-USE |
51. 6.48 INDIA MARKET ANALYSIS BY TARGET RARE DISEASES |
52. 6.49 JAPAN MARKET ANALYSIS BY TECHNOLOGY |
53. 6.50 JAPAN MARKET ANALYSIS BY APPLICATION |
54. 6.51 JAPAN MARKET ANALYSIS BY END-USE |
55. 6.52 JAPAN MARKET ANALYSIS BY TARGET RARE DISEASES |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END-USE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY TARGET RARE DISEASES |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY |
61. 6.58 MALAYSIA MARKET ANALYSIS BY APPLICATION |
62. 6.59 MALAYSIA MARKET ANALYSIS BY END-USE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY TARGET RARE DISEASES |
64. 6.61 THAILAND MARKET ANALYSIS BY TECHNOLOGY |
65. 6.62 THAILAND MARKET ANALYSIS BY APPLICATION |
66. 6.63 THAILAND MARKET ANALYSIS BY END-USE |
67. 6.64 THAILAND MARKET ANALYSIS BY TARGET RARE DISEASES |
68. 6.65 INDONESIA MARKET ANALYSIS BY TECHNOLOGY |
69. 6.66 INDONESIA MARKET ANALYSIS BY APPLICATION |
70. 6.67 INDONESIA MARKET ANALYSIS BY END-USE |
71. 6.68 INDONESIA MARKET ANALYSIS BY TARGET RARE DISEASES |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY |
73. 6.70 REST OF APAC MARKET ANALYSIS BY APPLICATION |
74. 6.71 REST OF APAC MARKET ANALYSIS BY END-USE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY TARGET RARE DISEASES |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TECHNOLOGY |
78. 6.75 BRAZIL MARKET ANALYSIS BY APPLICATION |
79. 6.76 BRAZIL MARKET ANALYSIS BY END-USE |
80. 6.77 BRAZIL MARKET ANALYSIS BY TARGET RARE DISEASES |
81. 6.78 MEXICO MARKET ANALYSIS BY TECHNOLOGY |
82. 6.79 MEXICO MARKET ANALYSIS BY APPLICATION |
83. 6.80 MEXICO MARKET ANALYSIS BY END-USE |
84. 6.81 MEXICO MARKET ANALYSIS BY TARGET RARE DISEASES |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY |
86. 6.83 ARGENTINA MARKET ANALYSIS BY APPLICATION |
87. 6.84 ARGENTINA MARKET ANALYSIS BY END-USE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY TARGET RARE DISEASES |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET RARE DISEASES |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END-USE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TARGET RARE DISEASES |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END-USE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TARGET RARE DISEASES |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY |
103. 6.100 REST OF MEA MARKET ANALYSIS BY APPLICATION |
104. 6.101 REST OF MEA MARKET ANALYSIS BY END-USE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY TARGET RARE DISEASES |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY END-USE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY END-USE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY TARGET RARE DISEASES, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY TARGET RARE DISEASES, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY END-USE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY TARGET RARE DISEASES, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Technology (USD Billion, 2025-2035)

CRISPR-Cas9
TALEN
Zinc Finger Nucleases
Meganucleases

Healthcare By Application (USD Billion, 2025-2035)

Gene Therapy
Cell Therapy
Genomic Research
Drug Development

Healthcare By End-Use (USD Billion, 2025-2035)

Pharmaceutical Companies
Research Institutions
Academic Institutions
Contract Research Organizations

Healthcare By Target Rare Diseases (USD Billion, 2025-2035)

Cystic Fibrosis
Sickle Cell Disease
Hemophilia
Duchenne Muscular Dystrophy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓